Display options
Cite
Bosch LJW, Trooskens G, Snaebjornsson P, et al. . Oncotarget. 2017;8(38):63140-63154doi: 10.18632/oncotarget.18702.
Bosch, L. J. W., Trooskens, G., Snaebjornsson, P., Coupé, V. M. H., Mongera, S., Haan, J. C., Richman, S. D., Koopman, M., Tol, J., de Meyer, T., Louwagie, J., Dehaspe, L., van Grieken, N. C. T., Ylstra, B., Verheul, H. M. W., van Engeland, M., Nagtegaal, I. D., Herman, J. G., Quirke, P., Seymour, M. T., Punt, C. J. A., van Criekinge, W., Carvalho, B., & Meijer, G. A. (2017). . Oncotarget, 8(38), 63140-63154. https://doi.org/10.18632/oncotarget.18702
Bosch, Linda J W, et al. "." Oncotarget vol. 8,38 (2017): 63140-63154. doi: https://doi.org/10.18632/oncotarget.18702
Bosch LJW, Trooskens G, Snaebjornsson P, Coupé VMH, Mongera S, Haan JC, Richman SD, Koopman M, Tol J, de Meyer T, Louwagie J, Dehaspe L, van Grieken NCT, Ylstra B, Verheul HMW, van Engeland M, Nagtegaal ID, Herman JG, Quirke P, Seymour MT, Punt CJA, van Criekinge W, Carvalho B, Meijer GA. . Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 08. PMID: 28968978; PMCID: PMC5609910.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 27;8(38):63140-63154. doi: 10.18632/oncotarget.18702. eCollection 2017 Sep 08.

[No title available]

Oncotarget

Linda J W Bosch, Geert Trooskens, Petur Snaebjornsson, Veerle M H Coupé, Sandra Mongera, Josien C Haan, Susan D Richman, Miriam Koopman, Jolien Tol, Tim de Meyer, Joost Louwagie, Luc Dehaspe, Nicole C T van Grieken, Bauke Ylstra, Henk M W Verheul, Manon van Engeland, Iris D Nagtegaal, James G Herman, Philip Quirke, Matthew T Seymour, Cornelis J A Punt, Wim van Criekinge, Beatriz Carvalho, Gerrit A Meijer

Affiliations

  1. Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands.
  2. Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  3. Department of Mathematical Modelling, Statistics and Bioinformatics, Ghent University, Ghent, Belgium.
  4. Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, The Netherlands.
  5. Pathology and Tumour Biology, University of Leeds, Leeds, UK.
  6. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands.
  7. Department of Internal Medicine, Jeroen Bosch Hospital, 's-Hertogenbosch, The Netherlands.
  8. MDxHealth, SA, Liège, Belgium.
  9. Genomics Core Facility, UZ Leuven, Leuven, Belgium.
  10. Department of Oncology, VU University Medical Center, Amsterdam, The Netherlands.
  11. Department of Pathology, GROW - School for Oncology and Developmental Biology and Maastricht University Medical Center, Maastricht, The Netherlands.
  12. Department of Pathology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands.
  13. Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  14. St James's Institute of Oncology, St James's University Hospital, Leeds, UK.
  15. Department of Medical Oncology, Academic Medical Center, Amsterdam, The Netherlands.

PMID: 28968978 PMCID: PMC5609910 DOI: 10.18632/oncotarget.18702

Abstract

Diversity in colorectal cancer biology is associated with variable responses to standard chemotherapy. We aimed to identify and validate DNA hypermethylated genes as predictive biomarkers for irinotecan treatment of metastatic CRC patients. Candidate genes were selected from 389 genes involved in DNA Damage Repair by correlation analyses between gene methylation status and drug response in 32 cell lines. A large series of samples (n=818) from two phase III clinical trials was used to evaluate these candidate genes by correlating methylation status to progression-free survival after treatment with first-line single-agent fluorouracil (Capecitabine or 5-fluorouracil) or combination chemotherapy (Capecitabine or 5-fluorouracil plus irinotecan (CAPIRI/FOLFIRI)). In the discovery (n=185) and initial validation set (n=166), patients with methylated

Keywords: CAIRO; TNFRSF10C; biomarker; chemotherapy; predictive

Conflict of interest statement

CONFLICTS OF INTEREST LJWB, GT, BC and GAM are listed as inventors on a patent application titled “Methylation of dcr1 as predictive marker for drug response” (applicant MdxHealth SA, application numb

References

  1. Lancet. 2007 Jul 14;370(9582):143-52 - PubMed
  2. Cancer Res. 2002 Apr 1;62(7):2157-61 - PubMed
  3. J Clin Oncol. 2008 Jun 1;26(16):2690-8 - PubMed
  4. Nat Rev Endocrinol. 2012 Apr 24;8(8):486-94 - PubMed
  5. Clin Ther. 2010 Mar;32(3):437-53 - PubMed
  6. J Clin Oncol. 2008 Apr 1;26(10 ):1626-34 - PubMed
  7. N Engl J Med. 2009 Feb 5;360(6):563-72 - PubMed
  8. Virchows Arch. 2007 May;450(5):529-37 - PubMed
  9. Nature. 2012 Jul 18;487(7407):330-7 - PubMed
  10. Eur J Cancer. 2009 Sep;45 Suppl 1:50-6 - PubMed
  11. Clin Chem. 2013 Jan;59(1):202-4 - PubMed
  12. J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52 - PubMed
  13. J Nutr Biochem. 2015 Aug;26(8):818-26 - PubMed
  14. Br J Cancer. 2011 Mar 15;104(6):1020-6 - PubMed
  15. Adv Nutr. 2012 Jan;3(1):21-38 - PubMed
  16. Clin Cancer Res. 2011 Mar 15;17(6):1535-45 - PubMed
  17. Proc Natl Acad Sci U S A. 2006 Jun 6;103(23 ):8822-7 - PubMed
  18. Curr Mol Med. 2014;14(7):833-40 - PubMed
  19. Cell Oncol. 2006;28(5-6):247-57 - PubMed
  20. Genet Test Mol Biomarkers. 2009 Feb;13(1):67-71 - PubMed
  21. Cell. 2010 Dec 23;143(7):1192, 1192.e1-2 - PubMed
  22. PLoS One. 2017 Apr 26;12 (4):e0176139 - PubMed
  23. Cell Oncol. 2007;29(4):351-9 - PubMed
  24. EPMA J. 2013 Feb 25;4(1):7 - PubMed
  25. Immunity. 1997 Dec;7(6):821-30 - PubMed
  26. Cancer Discov. 2012 May;2(5):401-4 - PubMed
  27. PLoS One. 2014 Feb 05;9(2):e86833 - PubMed
  28. J Clin Oncol. 2008 Jan 20;26(3):374-9 - PubMed
  29. Clin Cancer Res. 2003 Nov 1;9(14):5306-12 - PubMed
  30. Lancet. 2007 Jul 14;370(9582):135-42 - PubMed
  31. Nat Commun. 2014 Nov 14;5:5457 - PubMed
  32. Biochem Biophys Res Commun. 2013 Nov 29;441(4):743-50 - PubMed
  33. Cell Oncol. 2007;29(1):19-24 - PubMed

Publication Types